论文部分内容阅读
2017年9月,美国、欧盟和日本共批准52个新药,包括新分子实体、新有效成分、新生物制品、新增适应证及新剂型药物。对全球首次获得批准的新分子实体、新有效成分、新生物制品进行分析,重点介绍这些药物的临床研究结果和研发历史进程。
In September 2017, a total of 52 new drugs were approved by the United States, the European Union and Japan, including new molecular entities, new active ingredients, new biological products, new indications and new dosage forms. Analysis of the first new molecular entities, new active ingredients, and new biological products approved in the world, highlighting the clinical findings and R & D history of these drugs.